MIND1 System

DEVICE2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Device LatencyMental DisorderNervous System DiseasesSchizophrenia

Phase 2

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

CompletedNCT02219009

Otsuka Pharmaceutical Development & Commercialization, Inc.Mental Disorder, Nervous System Diseases, Schizophrenia

Start: 2014-08-31End: 2015-07-31Updated: 2018-08-15

Phase 4

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

CompletedNCT02404532

Otsuka Pharmaceutical Development & Commercialization, Inc.Device Latency

Start: 2015-02-28End: 2015-03-31Updated: 2018-08-03

Related Papers

Safety Evaluation in Iterative Development of Wearable Patches for Aripiprazole Tablets With Sensor: Pooled Analysis of Clinical Trials

JMIR Formative Research2023-09-232 citations

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole.

2016-10-1148 citations